Portal de Periódicos da CAPES

MP58-10 EVALUATION OF PREDICTIVE FACTORS OF ERECTILE DYSFUNCTION AFTER BRACHYTHERAPY FOR LOW RISK PROSTATE CANCER : PROSPECTIVE STUDY OF PATIENTS WITH A BASELINE IIEF5 SCORE > 16

2014; Lippincott Williams & Wilkins; Volume: 191; Issue: 4S Linguagem: Inglês

10.1016/j.juro.2014.02.1826

1527-3792

F. Delage, Le Fur Emmanuelle, Marie‐Aimée Perrouin‐Verbe, G. Papin, Aurélien Loiselle, M. Thoulouzan, Jean baptiste Coquet, J.P. Malhaire, Olivier Pradier, Georges Fournier, Antoine Valéri,

Prostate Cancer Diagnosis and Treatment

You have accessJournal of UrologyProstate Cancer: Localized VI1 Apr 2014MP58-10 EVALUATION OF PREDICTIVE FACTORS OF ERECTILE DYSFUNCTION AFTER BRACHYTHERAPY FOR LOW RISK PROSTATE CANCER : PROSPECTIVE STUDY OF PATIENTS WITH A BASELINE IIEF5 SCORE > 16 Francky Delage, Le Fur Emmanuelle, Marie-Aimée Perrouin-Verbe, Gregory Papin, Aurélien Loiselle, Maxime Thoulouzan, Jean baptiste Coquet, Jean Pierre Malhaire, Olivier Pradier, Georges Fournier, and Antoine Valeri Francky DelageFrancky Delage More articles by this author , Le Fur EmmanuelleLe Fur Emmanuelle More articles by this author , Marie-Aimée Perrouin-VerbeMarie-Aimée Perrouin-Verbe More articles by this author , Gregory PapinGregory Papin More articles by this author , Aurélien LoiselleAurélien Loiselle More articles by this author , Maxime ThoulouzanMaxime Thoulouzan More articles by this author , Jean baptiste CoquetJean baptiste Coquet More articles by this author , Jean Pierre MalhaireJean Pierre Malhaire More articles by this author , Olivier PradierOlivier Pradier More articles by this author , Georges FournierGeorges Fournier More articles by this author , and Antoine ValeriAntoine Valeri More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1826AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Low dose brachytherapy (BrT) using iodine-125 is a validated option for treatment of localized prostate cancer (CaP). Few studies have been performed on erectile dysfunction (ED) after BrT. The aim of this study was to assess prospectively the evolution of erectile function and identify predictive factors at 2 years (2y) after BrT using IIEF5 score, in patients with a baseline IIEF5 score > 16. METHODS Between 02/2007 and 07/2012, 179 patients underwent an exclusive BrT (loose seeds, realtime planning, prescribed dose 160 Gy). Neo-adjuvant hormonotherapy (HT) and post-brachytherapy intake phosphodiesterase inhibitors (IPDE5i) were not exclusion criteria. Erectile function (EF) was evaluated using a scoring validated questionnaire (IIEF5) before the surgical implantation and at 1y and 2y post-operatively. RESULTS Of the 179 patients, 102 (64.2%) had a baseline IIEF5>16, (including 13 (12.7%) with HT) while 94 (92%) and 62 (61%) may be assessed at 1y and 2y respectively. At 1y (Table), 51.1% maintained an IIEF5>16 [including 17 patients (18%) treated with phospho-diesterase 5 inhibitors (PDE5i)]. There was a 5.6 mean variation of IIEF5 (pre-op vs 1y) from 21.4 to 15,8 (p < 0.0001). At 2y, (Table), 53.2% had an IIEF5 >16 and 80.6% had an IIEF5 >12. Severe ED was reported in only 14.5% of the patients. All patients who were treated with PDE5i (27%) could have sexual intercourse (IIEF5 >12). There was no statistical difference between the mean IIEF5 at 1y and 2y. Erectile function at baseline was the only predictive factor of ED in multivariate analysis. Indeed, for patients without ED at baseline (n=52; IIEF5 >21), 69.7% had an IIEF5 >16 at 2y vs 34.5% for patients with an initial IIEF5 17-21 (table) (p=0,0005) ; odds ratio= 6 (CI : 1,4–25)]. Diabetes seemed to decrease EF at 2y: IIEF5 >16, 14.3% vs 58.2% (p=0,04), but that was not confirmed in multivariate analysis. Age, HT, prostate volume and history of vascular disease did not influence the postoperative EF. CONCLUSIONS During the first 2 years after BrT, (including patients under PDE5i), severe ED was relatively rare (14.5%). More than 50% of patients maintained an IIEF5 >16. The only predictive factor of ED in multivariate analysis was the erectile function at baseline. No or mild ED IIEF5>16 Mild moderate ED IIEF5 16-12 Moderate ED IIEF5 11-8 Severe ED IIEF5 21 at baseline 1y n=49 35 (71.4%) 7 (14.3%) 1 (2%) 6 (12.2%) 2y n=33 23 (69.7%) 6 (18.2%) 1 (3%) 3 (9.1%) IIEF5 : 17-21 at baseline 1y n=45 13 (28.9%) 16 (35.6%) 9 (20%) 7 (15.6%) 2y n=29 10 (34.5%) 11 (37.9%) 2 (6.9%) 6 (20.7%) © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e661-e662 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Francky Delage More articles by this author Le Fur Emmanuelle More articles by this author Marie-Aimée Perrouin-Verbe More articles by this author Gregory Papin More articles by this author Aurélien Loiselle More articles by this author Maxime Thoulouzan More articles by this author Jean baptiste Coquet More articles by this author Jean Pierre Malhaire More articles by this author Olivier Pradier More articles by this author Georges Fournier More articles by this author Antoine Valeri More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...